Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus AUREOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus AUREOMYCIN.
ACTICLATE CAP vs AUREOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking aminoacyl-tRNA binding.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
250-500 mg orally every 6 hours; or 10-20 mg/kg/day intravenously divided every 12 hours
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Terminal elimination half-life: 8–12 hours (prolonged in renal impairment; may extend to 20–30 hours in anuria)
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Renal (70% unchanged), biliary/fecal (30% as metabolites and unchanged drug)
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic